|Master Investor Magazine
Never miss an issue of Master Investor Magazine – sign-up now for free!
AIM-listed Oxford Biodynamics (LON:OBD) has seen its share price drop by 4.62% to 155p (as of 12:40 BST) after its operationg loss for the six months to 31st March widened to £1.7 million. Revenues rose slightly, but the business continued to invest for future growth, including the formation of a US subsidiary.
CEO Christian Hoyer Millar said: “We have made further strong operational and commercial progress in the first half of the year. Our EpiSwitch™ technology platform has been adopted by prestigious clinical trials in the US and UK; we have enhanced the senior leadership team and Board to drive the next phase of growth; and have entered into promising new collaboration agreements. We were also delighted to be awarded the prestigious Queen’s Award for Enterprise: Innovation, a great recognition of the value our EpiSwitch™ platform has generated to date“.
The Master Investor Show 2020 tickets are now available. Join us at the Business Design Centre on Saturday 28 March 2020.
Book your FREE tickets today using code: MIBLOG